IL-SUREWERX
11.7.2024 23:01:29 CEST | Business Wire | Press release
SureWerx®, a leading global provider of safety, tool & equipment products, announced today that it has acquired FALL SAFE®. Terms were not disclosed.
Based in Porto, Portugal, FALL SAFE® is a global leader of critical-use personal protective equipment, specializing in fall protection equipment and systems. Since 2003, the company has been recognized as a category leader and innovator of highly technical and functional safety products for diverse end markets. FALL SAFE® designs and manufactures a wide variety of fall protection safety products including harnesses, self-retracting lifelines (SRL’s), descenders, belts, anchors, ropes, lifelines as well as other technical fall protection products including various safety accessories. FALL SAFE® continues to lead through innovation, with the sole purpose of keeping workers safe and protecting the lives of countless professionals working at heights around the globe. As part of the transaction, FALL SAFE® TRAINING, a fully certified training facility, helps to train workers at heights from around the globe.
“Adding FALL SAFE to our growing, world-class portfolio of SureWerx brands moves us further toward our goal of becoming the global leader in Safety and Productivity,” said SureWerx CEO, Chris Baby. “FALL SAFE brings us one step closer to building a robust and innovative Fall Protection portfolio as part of the SureWerx platform. FALL SAFE’s expertise in the most technical and demanding portion of the Fall Protection market around the globe sets them apart from their competition. We are thrilled to be adding this highly respected brand to our market-leading portfolio of best-in-class safety products.”
“FALL SAFE has always focused on delivering innovative, performance-driven products and solutions to end users through its distribution partners,” said FALL SAFE Founders, Jan and Paula Ekman. “We are thrilled to be partnering with SureWerx, a company that holds the same values and commitment to worker safety as FALL SAFE. Their reach into the global industrial markets and access to over 4,000 distributors across multiple channels will undoubtedly accelerate growth of the FALL SAFE brand. We are in good hands - the future for FALL SAFE has never been brighter!”
About SureWerx
Co-headquartered in Vancouver, Canada, and Elgin, Illinois, SureWerx is a leading global manufacturer of professional safety products, tools, and equipment. SureWerx markets its safety products under multiple brands including Jackson Safety®, Sellstrom®, Pioneer®, PeakWorks®, ADA Solutions®, Armor Tile, Access Tile, Due North®, K1 Series®, Avenger, Nautilus®, MEGAComfort, NEOS®, Oberon and now FALL SAFE®.
SureWerx offers unparalleled access to its brands through its distributor network servicing the industrial, construction, safety, electrical, utilities, resources, transportation, automotive aftermarket, and food production markets globally. For more information visit: www.surewerx.com.
About FALL SAFE
Headquartered in Porto, Portugal and founded in 2003, FALL SAFE specializes in designing and manufacturing innovative, performance-based working at heights safety products for professional workers. Products and training serve most industrial and construction channels and users around the globe. For more information please visit: www.fallsafe-online.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711650843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom